Trials / Terminated
TerminatedNCT04820023
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
A Phase 1/2, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BBT-176 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Agent
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Bridge Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is the first-in-human study of BBT-176. The purpose of this trial is to investigate the safety and tolerability of BBT-176 (Part 1) and to evaluate the anti-tumor activity of BBT-176 (Part 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBT-176, QD | BBT-176 given orally alone, QD |
| DRUG | BBT-176, BID | BBT-176 given orally alone, BID |
Timeline
- Start date
- 2021-04-02
- Primary completion
- 2023-11-29
- Completion
- 2023-11-29
- First posted
- 2021-03-29
- Last updated
- 2025-06-06
- Results posted
- 2025-06-06
Locations
4 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04820023. Inclusion in this directory is not an endorsement.